文献速递重症综合管理与镇静镇痛儿科与产科急症

院前使用氯胺酮治疗严重激越患者的精神科结局

Psychiatric Outcomes of Patients With Severe Agitation Following Administration of Prehospital Ketamine.
PubMed 文献 · Acad Emerg Med · 2019-04-03
一句话结论回顾性队列显示,院前严重激越使用氯胺酮较苯二氮䓬类未增加急诊精神科评估或精神科住院率,无论有无精神病史。

本研究为两所三级学术医疗中心的回顾性队列研究,纳入2014年1月1日至2016年6月30日因严重激越需院前镇静的患者,比较肌注或静注氯胺酮与肌注或静注苯二氮䓬类的精神科结局。主要终点精神科住院率两组无统计学显著差异(氯胺酮6.8% vs 苯二氮䓬类2.4%,差值4.3%,95%CI -2%至12%,p=0.23),急诊精神科评估率亦无显著差异(8.6% vs 15%,差值-6.8%,95%CI -18%至5%,p=0.23)。精神分裂症亚组样本小(n=16),氯胺酮组精神科住院(17% vs 10%,差值6.7%,95%CI -46%至79%,p=0.63)和急诊精神科评估(17% vs 50%,差值-33%,95%CI -100%至33%,p=0.55)均未显著高于苯二氮䓬类组。非精神科住院率两组无显著差异(35% vs 51%,p=0.082),但苯二氮䓬类组非精神科住院主要由插管驱动(63% vs 3.8%,差值59%,95%CI 38%至79%,p<0.001)。

要点

  • 院前严重激越使用氯胺酮与苯二氮䓬类相比,精神科住院率无统计学显著差异(6.8% vs 2.4%,差值4.3%,95%CI -2%至12%,p=0.23)。
  • 急诊精神科评估率两组亦无显著差异(氯胺酮8.6% vs 苯二氮䓬类15%,差值-6.8%,95%CI -18%至5%,p=0.23)。
  • 精神分裂症亚组(n=16)中,氯胺酮组精神科住院(17% vs 10%,p=0.63)和急诊精神科评估(17% vs 50%,p=0.55)未显著高于苯二氮䓬类组。
  • 苯二氮䓬类组非精神科住院率35% vs 氯胺酮组51%(p=0.082),其中苯二氮䓬类组住院主要由插管驱动(63% vs 3.8%,差值59%,95%CI 38%至79%,p<0.001)。

适用人群与场景

  • 2014年1月1日至2016年6月30日在两所三级学术医疗中心因严重激越需院前镇静并接受肌注或静注氯胺酮或肌注或静注苯二氮䓬类的患者,共141例次纳入。

研究设计与关键结果

  • 研究类型为回顾性队列研究,在两所三级学术医疗中心开展,共141例次患者纳入,其中59例次(42%)接受院前氯胺酮。
  • 主要终点精神科住院率:氯胺酮组6.8% vs 苯二氮䓬类组2.4%,差值4.3%(95%CI -2%至12%,p=0.23),无统计学显著差异。
  • 次要终点急诊精神科评估率:氯胺酮组8.6% vs 苯二氮䓬类组15%,差值-6.8%(95%CI -18%至5%,p=0.23),无统计学显著差异。
  • 精神分裂症亚组(n=16):氯胺酮组精神科住院17% vs 苯二氮䓬类组10%,差值6.7%(95%CI -46%至79%,p=0.63);急诊精神科评估17% vs 50%,差值-33%(95%CI -100%至33%,p=0.55),均无统计学显著差异。
  • 非精神科住院率:氯胺酮组35% vs 苯二氮䓬类组51%(p=0.082),无统计学显著差异;苯二氮䓬类组非精神科住院中插管占63% vs 氯胺酮组3.8%,差值59%(95%CI 38%至79%,p<0.001)。

证据类型、等级与局限

  • 证据类型为回顾性队列研究,采用广义估计方程和Fisher精确检验比较队列。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,与苯二氮䓬类治疗相比,院前严重激越使用氯胺酮与急诊精神科评估率或精神科住院率增加无关,无论患者有无精神病史。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Ketamine is an emerging drug used in the management of undifferentiated, severe agitation in the prehospital setting. However, prior work has indicated that ketamine may exacerbate psychotic symptoms in patients with schizophrenia. The objective of this study was to describe psychiatric outcomes in patients who receive prehospital ketamine for severe agitation.

METHODS: This is a retrospective cohort study, conducted at two tertiary academic medical centers, utilizing chart review of patients requiring prehospital sedation for severe agitation from January 1, 2014, to June 30, 2016. Patients received either intramuscular (IM) versus intravenous (IV) ketamine or IM versus IV benzodiazepine. The primary outcome was psychiatric inpatient admission with secondary outcomes including ED psychiatric evaluation and nonpsychiatric inpatient admission. Generalized estimating equations and Fisher's exact tests were used to compare cohorts.

RESULTS: During the study period, 141 patient encounters met inclusion with 59 (42%) receiving prehospital ketamine. There were no statistically significant differences between the ketamine and benzodiazepine cohorts for psychiatric inpatient admission (6.8% vs. 2.4%, difference = 4.3%, 95% CI = -2% to 12%, p = 0.23) or ED psychiatric evaluation (8.6% vs. 15%, difference = -6.8%, 95% CI = -18% to 5%, p = 0.23). Patients with schizophrenia who received ketamine did not require psychiatric inpatient admission (17% vs. 10%, difference = 6.7%, 95% CI = -46% to 79%, p = 0.63) or ED psychiatric evaluation (17% vs. 50%, difference = -33%, 95% CI = -100% to 33%, p = 0.55) significantly more than those who received benzodiazepines, although the subgroup was small (n = 16). While there was no significant difference in the nonpsychiatric admission rate between the ketamine and benzodiazepine cohorts (35% vs. 51%, p = 0.082), nonpsychiatric admissions in the benzodiazepine cohort were largely driven by intubation (63% vs. 3.8%, difference = 59%, 95% CI = 38% to 79%, p < 0.001).

CONCLUSIONS: Administration of prehospital ketamine for severe agitation was not associated with an increase in the rate of psychiatric evaluation in the emergency department or psychiatric inpatient admission when compared with benzodiazepine treatment, regardless of the patient's psychiatric history.

来源:Acad Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Lebin JA, Akhavan AR, Hippe DS, et al. Psychiatric Outcomes of Patients With Severe Agitation Following Administration of Prehospital Ketamine. Acad Emerg Med. 2019. PMID: 30873690. doi:10.1111/acem.13725

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。